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Abstract
Introduction: Donepezil is indicated for the symptomatic treatment of mild to moderate Alzheimer’s disease. It is a specific and
reversible inhibitor of acetylcholinesterase (AChE); by increasing levels of available acetylcholine, donepezil may compensate for the loss
of functioning cholinergic brain cells.
Aims: This review evaluates the clinical impact of donepezil by assessing randomized controlled and open-label naturalistic trials, as
well as observational studies. A broad perspective is gained of its effectiveness on various outcomes.
Evidence review: There is strong evidence that donepezil has efficacy against the three major domains of Alzheimer’s disease
symptoms, namely functional ability, behavior, and cognition. The strongest evidence is for improvement or less deterioration in global
outcomes and cognition in the short to medium term. There is limited evidence that improved global outcomes are maintained in the
long term and clear evidence to support long-term maintenance of cognitive benefits. Also, donepezil appears to maintain function in
the long term and there is some level 1 and 2 evidence of improved or limited deterioration in behavior or mood in the short to medium
term. Despite donepezil’s effects on major symptoms of Alzheimer’s disease, its impact on patients’ quality of life has not been
consistently demonstrated, perhaps reflecting the difficulty of assessing this aspect in this patient population. Donepezil may also lessen
caregiver burden. Donepezil has some effect on markers of brain function, but more data are needed to confirm a neuroprotective effect.
There is limited and conflicting evidence that long-term donepezil treatment delays time to institutionalization. There is some evidence
that donepezil may be cost effective, especially when unpaid caregiver costs are considered. Donepezil is generally safe and well
tolerated.
Clinical value: AChE inhibitors are the only agents recommended for the treatment of cognitive decline in patients with mild to moderate
Alzheimer’s disease. Donepezil is more effective than placebo and is well tolerated in improving the major symptoms of this disease.
Improvements are usually modest, although stabilization of cognitive and functional symptoms with donepezil can also be considered
an important clinical outcome. Donepezil may lessen caregiver burden. Donepezil may also be cost effective, especially when unpaid
caregiver costs are considered. More data are required from randomized controlled trials with long-term follow-up to confirm its cost
effectiveness and impact on quality of life, disease progression, and time to institutionalization. 
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Core evidence clinical impact summary for donepezil in mild to moderate Alzheimer’s disease
Outcome measure Evidence Implications
Patient-oriented evidence
Global
Improvement in global outcomes in the short to
medium term
Substantial Donepezil is more effective than placebo in improving global outcomes in the short to
medium term
Maintenance of improvements in global
outcomes in the long term
Limited Donepezil may be more effective than placebo in maintaining global outcomes in the long
term
Stabilization of symptoms in the long term Substantial Donepezil treatment stabilizes cognitive and functional symptoms in comparison with
placebo in the long term
continued overleaf…Scope, aims, and objectives
Donepezil (Aricept®, Eisai and Pfizer) is indicated for the
symptomatic treatment of mild to moderate Alzheimer’s disease.
It is a specific and reversible inhibitor of acetylcholinesterase
(AChE), thus inhibiting acetylcholine hydrolysis. By maintaining
levels of acetylcholine, donepezil may help compensate for the
loss of functioning cholinergic neurons in Alzheimer’s disease.
Of the available AChE inhibitors (AChEIs), only tacrine (Cognex®)
has been on the market longer than donepezil; tacrine was
approved in 1993 but is rarely prescribed today because of
associated adverse events, including possible liver damage.
Donepezil was approved in 1996/1997, and rivastigmine (Exelon®)
and galantamine (Razadyne®/Reminyl®) were approved in 2000
and 2001, respectively. 
This article audits the clinical impact of donepezil by assessing
the results of randomized controlled and open-label naturalistic
trials, as well as observational studies. A broad perspective is
gained of its effectiveness on outcomes that include global
outcomes, cognition, function, behavior/mood, disease
progression, time to institutionalization, quality of life, caregiver
burden, and tolerability.
Use in patients with mild cognitive impairment or severe
Alzheimer’s disease was excluded, as these indications are not
presently approved. However, as indicated in the tables, some of
the included reviews and studies combined results from patients
with mild, moderate, and severe Alzheimer’s disease, and it was
not possible to separate data from patients with mild to moderate
symptoms. 
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…table continued
Outcome measure Evidence Implications
Cognition
Improvement in cognition in the short to medium
term
Substantial Donepezil produces modest improvements in cognition in comparison with placebo in the
short to medium term
Maintenance of improvements in cognition in the
long term
Clear Donepezil maintains improvements in cognition in comparison with placebo in the long
term 
Function
Improvement in function (activities of daily living)
in the short to medium term
Some Donepezil may be more effective than placebo in improving function in the short to
medium term
Improvement in function (activities of daily living)
in the long term
Substantial Donepezil produces improved or less deterioration in functional ability in comparison with
placebo in the long term
Behavior/mood
Improvement in behavior/mood in the short to
medium term
Some Donepezil is more effective than placebo in improving or limiting deterioration in behavior
or mood in the short to medium term
Improvement in behavior/mood in the long term No evidence
Tolerability
Tolerability Substantial Donepezil is well tolerated; the most common adverse events are predictable from its
cholinergic mechanism of action
Lower incidence of adverse events in a
naturalistic trial setting
Some The incidence of adverse effects may be lower outside of the clinical trial setting
Other
Delayed disease progression Insufficient Donepezil does not have an effect on the progression of disability or death rates
Delayed time to institutionalization Limited Further confirmation of effectiveness required
Improvement in quality of life Insufficient Evidence is divided on whether donepezil improves quality of life
Caregiver burden lessened Some Donepezil may lessen caregiver burden in terms of caring time spent each day
Disease-oriented evidence
Delayed disease progression Some Donepezil has an effect on indirect markers of disease progression, such as regional
cerebral blood flow, 123I quinuclidinyl benzilate, quantitative electroencephalogram, and
the degree of hippocampal atrophy, in comparison with matched control groups
Economic evidence
Cost effectiveness in Alzheimer’s disease patients Some Donepezil may be cost effective, especially when unpaid caregiver costs are considered 197
Methods
Searches of the English language literature were conducted
between March 21 and 31, 2005, on August 2, 2005, and
September 12, 2005, in the following databases. The search
strategy was “donepezil AND (Alzheimer OR dementia)” unless
otherwise stated. The cut-off date was from the beginning of the
database to the date of the search unless otherwise stated.
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi 
• Database of Abstracts of Reviews of Effects (DARE), National
Health Service (NHS) Economic Evaluation Database
(NHSEED), Health Technology Assessment (HTA),
http://www.york.ac.uk/inst/crd/darehp.htm. All three databases
were searched together. All fields searched 
• NHS HTA, http://www.ncchta.org 
• National Guideline Clearing House, http://www.guideline.gov
• National Institute for Health and Clinical Excellence (NICE),
http://www.nice.org.uk
• Cochrane Database of Systematic Reviews (CDSR),
http://www.cochrane.org/index0.htm
• Clinical Evidence (BMJ), http://www.clinicalevidence.com
After removal of duplicates, a total of 613 records were retrieved
from the PubMed, DARE, NHSEED, HTA, and NHS HTA databases.
Records were manually reviewed and a total of 467 records were
excluded: nonsystematic reviews (n=202); animal or mechanism of
action studies (n=35); studies in patients other than Alzheimer’s
disease patients, or Alzheimer’s disease not specified, or
Alzheimer’s disease in Down’s syndrome patients (n=109); studies in
patients with severe or advanced Alzheimer’s disease (n=10); letters,
editorials, comment, and corrections (n=66); articles that mentioned
donepezil but did not investigate its clinical use, or donepezil results
were not reported separately (n=19); studies assessing the
prediction of response to treatment (n=12); and studies of donepezil
treatment cessation or switch to another treatment (n=14). The
remaining 146 records were included in the review.
Three sets of clinical guidelines were identified from the National
Guidelines Clearinghouse (APA 1997; Doody et al. 2001b;
California Workgroup 2002). The NICE Appraisal Consultation
Document for Alzheimer’s disease (NICE 2005), the Cochrane
Collaboration review of donepezil for dementia due to Alzheimer’s
disease (Birks & Harvey 2003), and the Clinical Evidence review of
dementia (Warner et al. 2004) were also included as systematic
reviews. The NICE Appraisal Consultation Document for
Alzheimer’s disease was issued in March 2005 and was prepared
for comment from formal consultees (NICE 2005). Preliminary
guidance was issued in January 2006 (NICE 2006). The Cochrane
Collaboration review and Clinical Evidence review of dementia
were duplicated in the PubMed database. Therefore, a total of
150 records were included in the review (Table 1).
For each outcome, preference was given to level 1 and 2 evidence
(see Editorial Information on inside back cover). However, as the
review aimed to gain a broad perspective of the effectiveness of
donepezil on outcomes, level 3 and 4 evidence was also
assessed, particularly where level 1 and 2 evidence was lacking
or conflicting. Outcomes from original level 2 or 3 studies,
covered in level 1 evidence, were not considered separately in this
review. As a result, 12 level 2 papers (Rogers & Friedhoff 1996;
Rogers et al. 1998a; Rogers et al. 1998b; Burns et al. 1999;
Greenberg et al. 2000; Homma et al. 2000; Mohs et al. 2001;
Tariot et al. 2001; Winblad et al. 2001; Wilkinson et al. 2002; Tune
et al. 2003; Wilcock et al. 2003) and three level 3 papers (Rogers
& Friedhoff 1998; Rogers et al. 2000; Doody et al. 2001a), which
presented data on outcomes for which substantial level 1
evidence was identified, are not considered in this review. 
Disease overview
Alzheimer’s disease is a type of dementia characterized by
deterioration in functional ability [activities of daily living (ADL)],
behavior and mood, and cognition and memory. It is a progressive
disorder that usually develops slowly but steadily over a period of
several years. Its onset is frequently after 65 years of age and, as
age advances, its incidence increases rapidly, approximately
doubling every 5 years (WHO 2001). Median survival from initial
diagnosis is approximately 4–6 years, which is about half as long
as survival among people of a similar age without dementia
(Larson et al. 2004).
Diagnosis
There is no simple test that provides a definitive diagnosis of
Alzheimer’s disease. Also, the onset of Alzheimer’s is often so
gradual and the early signs so mild that they can easily be
mistaken for normal mental aging. However, it is important to
diagnose Alzheimer’s disease as early as possible to give those
affected by the disease and their caregivers the opportunity to
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Category Number of records (full papers)
Initial search 617
records excluded 467
records included 150
Level 1 clinical evidence 20
Level 2 clinical evidence  23
Level ≥3 clinical evidence 98
trials other than RCT 79
case reports 19
Clinical guidelines 3
Economic evidence 6
For definition of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review
 prepare for disease progression, and to increase the likelihood of
gaining benefit from existing treatments.
Diagnosis depends largely on the elimination of other systemic,
psychiatric, and neurologic causes of dementia by clinical and
laboratory investigation. This is accompanied by a careful
assessment of the family and personal history of the individual and
their symptoms. The classic clinical features of Alzheimer’s
disease can be categorized into three domains: function (ADL),
behavior, and cognition. Loss of higher level function involving
complex decision making and activities (e.g. managing finances) is
followed in advanced phases by abnormalities of basic ADL, such
as eating, grooming, and using the toilet (reviewed by Cummings
2004). Behavioral disturbances also progress, and mood change
and apathy are early markers of the disease. Psychosis and
agitation are characteristic of the middle or late phases of the
disease (Cummings 2004). Moreover, primary caregivers, who are
usually family members, are documented to suffer frequently from
stress, insomnia, and fatigue and as a consequence may require
medical care themselves (Leung et al. 2003).
The scales used most frequently in clinical trials to measure the
three key symptom domains in Alzheimer’s disease include:
• function (ADL): Progressive Deterioration Scale (PDS),
Instrumental Activities of Daily Living (IADL), Disability
Assessment for Dementia (DAD), Katz ADL
• behavior: Neuropsychiatric Inventory (NPI), Behavioral
Pathology in Alzheimer's Disease (BEHAVE-AD)
• cognition: cognitive part of the Alzheimer’s Disease Assessment
Scale (ADAS-cog), Mini Mental State Examination (MMSE).
Scales to measure severity are also used frequently to indicate
effects on disease progression, such as the Clinical Dementia
Rating (CDR) scale, and Global Deterioration Scale (GDS). These
symptom and severity scales are readily available but suffer from
variability due to examiner subjectivity. More objective techniques
that can be used to confirm diagnosis by excluding dementia due
to other causes include computed tomography (CT), magnetic
resonance imaging (MRI), and positron emission tomography
(PET) of the brain. The definitive pathologic hallmarks of
Alzheimer’s disease, the presence of amyloid plaques and
neurofibrillary tangles, can only be detected currently by
examining the brain at postmortem.
Prevalence
Estimated values for the prevalence of Alzheimer’s disease vary
from 1 to 5%, partly because of differences in age samples and
diagnostic criteria among the studies conducted (WHO 2001). A
World Health Organization (WHO) study estimated a prevalence of
5% for men and 6% for women in those above 60 years (WHO
2001); it is thought that more women than men are encountered
with Alzheimer’s disease because of greater female longevity. A
separate study estimated that 6.1% of the worldwide population
aged 65 years and older had Alzheimer’s disease or another form
of dementia in 2000 (Wimo et al. 2003a). The prevalence of
Alzheimer’s disease increases dramatically with age; of
individuals aged between 75 and 84 years, up to 20% may be
affected, while a prevalence of nearly 50% has been reported in
those aged over 85 years (Evans et al. 1989).
The prevalence of Alzheimer’s disease in the USA is predicted to
increase from 4.5 million in 2000 to 13.2 million by 2050 (Hebert
et al. 2003). This trend is likely to be repeated in many other
countries where numbers of people aged over 65 years are
expected to increase and be accompanied by disproportionate
increases in dementia. For example, in 2000, the percentage of
population aged 65 and over was 15.5% in Europe and 12.6% in
North America (Kinsella & Velkoff 2001). The projected
percentages for 2030 are 24.3 and 20.3%, respectively (Table 2).
Moreover, significant increases in the numbers of older people
are expected in developing countries, many of whose
populations are aging at a much faster rate than in the developed
world (Kinsella & Velkoff 2001). Therefore, the contribution of
Alzheimer’s disease to the global burden of disease is likely to
increase in the coming years. 
The burden of illness
The progression of Alzheimer’s disease is accompanied by
significant losses in cognitive and functional ability; consequently,
many patients require a high level of care. Also, as median
survival after diagnosis is 4–6 years (Larson et al. 2004), care is
usually required long term. The shift from institutional to
community care in many countries has increased the burden
placed on family caregivers, who are often elderly relatives
(Alzheimer’s Society 2004). For example, a UK survey (“Right from
the start”) of over 2000 caregivers of patients with dementia found
that 49% were over 70 years old (Alzheimer’s Society 2004). The
caregiver burden encompasses physical, psychologic or
emotional, social, and financial problems, and these problems
appear to be experienced frequently. In the “Right from the start”
survey, 60% of caregivers reported that they were suffering ill
health or psychologic problems as a direct result of caring
(Alzheimer’s Society 2004). 
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Region Percentage population aged ≥65 years
2000 (actual) 2030 (projected)
Europe 15.5 24.3
North America 12.6 20.3
Oceania 10.2 16.3
Asia 6.0 12.0
Latin America/Caribbean 5.5 11.6
Near East/North Africa 4.3 8.1
Sub-Saharan Africa 2.9 3.7
Table 2 | Predicted increases in the percentage of population
aged 65 years and over from the year 2000 to 2030
(adapted from Kinsella & Velkoff 2001)
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The value of services provided by unpaid caregivers is
significant; in the UK, an estimate of the value in 2001–2002 was
£57.4 billion (Alzheimer’s Society 2004). In the USA, the average
lifetime cost of care for an individual with Alzheimer’s disease
was estimated at $US170 000, of which an average $US12 500
was paid by caregivers themselves (Alzheimer’s Association
2004). Many caregivers have to use private savings and assets to
meet the cost of caring for a relative, and to pay for practical help
and support such as home care or respite care (Alzheimer’s
Association 2004; Alzheimer’s Society 2004). Also, caregivers in
paid work may lose out on income and promotion while those
who give up work risk losing work skills, pension rights, and
opportunities for reemployment (Alzheimer’s Society 2004). An
Alzheimer’s Association report estimates that Alzheimer’s
disease costs American businesses more than $US61 billion a
year, of which $US24.6 billion covers Alzheimer’s disease
healthcare and $US36.5 billion covers costs related to
caregivers, including lost productivity, absenteeism, and worker
replacement (Koppel 2002). 
Alzheimer’s disease also incurs a significant burden in terms of
medical, institutional, and welfare resources. A report
commissioned by the Alzheimer’s Association in the USA
predicted that by 2010 Medicare costs for beneficiaries with
Alzheimer’s disease would increase 54.5%, from $US31.9 billion
in 2000 to $US49.3 billion (Alzheimer’s Association 2001).
Additionally, Medicaid expenditures on residential dementia care
would increase 80%, from $US18.2 billion to $US33 billion in
2010 (Alzheimer’s Association 2001). 
Pathophysiology
Alzheimer’s disease is characterized by shrinkage of the brain due
to cell loss, especially in the areas concerned with memory,
rational thought, and language development (St George-Hyslop
2000). Theories for the cause of brain cell loss have suggested a
role for factors such as tau-protein abnormalities (Liou et al.
2003), metals (Casadesus et al. 2004), vascular factors (Fernando
& Ince 2004), and viral infections (Ringheim & Conant 2004). One
theory in particular has increasing support: the “amyloid cascade
hypothesis,” which suggests that the production and
accumulation of beta-amyloid peptide plays a key role
(Cummings 2004; Zlokovic et al. 2005). The observations that
support beta-amyloid as the common initiating factor in
Alzheimer’s disease include the following:
• all Alzheimer’s disease patients have many amyloid plaques
containing degenerating nerve endings, and their plaque count
far exceeds that found in normal aging (Perry et al. 1978)
• the amount of amyloid plaques in “thinking” regions of the
brain correlates in some studies with the degree of mental
impairment (Cummings & Cotman 1995)
• the genes now known to cause Alzheimer’s disease have been
shown to increase beta-amyloid production (APP, encoding
amyloid precursor protein; PSEN, encoding presenilin) or
deposition (ApoE4, encoding apolipoprotein E4) (Gandy 2005).
Beta-amyloid protein is thought to exert neurotoxic effects via
secondary mechanisms, including the formation of neurofibrillary
tangles, oxidation and lipid peroxidation, glutamatergic
excitotoxicity, inflammation, and activation of apoptotic cell
death (Cummings 2004; Zlokovic et al. 2005) (Fig. 1). Among
nuclear groups of neurons responsible for maintenance of
specific transmitter systems, cell dysfunction and cell death
lead to deficits in the neurotransmitters acetylcholine,
norepinephrine, and serotonin (Palmer et al. 1988; Pappas et al.
2000; Cummings 2004).
Observations of damage and deficits in the cholinergic system
provided the rationale for the development of AChEIs, which
inhibit the hydrolysis of acetylcholine. By increasing levels of
available acetylcholine, AChEIs may help to compensate for the
loss of functioning cholinergic neurons.
Current therapy options
There is no cure for Alzheimer’s disease, but there are treatments
that may improve symptoms and may even delay their
progression in the early and middle stages of the disease,
allowing patients to maintain certain daily functions for longer.
Various country- or region-specific, evidence-based guidelines
have been developed for the treatment of Alzheimer’s disease.
These make recommendations that vary according to available
resources, funding practices, and local practice. In general,
however, the guidelines provide recommendations regarding
psychiatric management, psychosocial treatments, and the
treatment of specific target symptoms. 
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Fig. 1 | The amyloid cascade hypothesis (adapted from
Cummings 2004)In this section, the content of several guidelines developed in the
USA is described (APA 1997; Doody et al. 2001b; California
Workgroup 2002). These guidelines emphasize the need for
regular monitoring of symptoms to allow treatment plans to
evolve and address newly emerging issues associated with this
progressive condition (APA 1997; California Workgroup 2002).
Also, as patients with Alzheimer’s disease display a broad range
of functional, cognitive, and behavioral symptoms, an
individualized and multimodal treatment plan is required (APA
1997; Doody et al. 2001b; California Workgroup 2002).
General treatment principles
The first step recommended in guidelines is the development of a
treatment plan taking into account the stage of illness and
severity of problems (APA 1997; California Workgroup 2002). At
each stage of impairment, certain symptoms should be
anticipated (Table 3), and the patient and their family should be
helped to plan for future symptoms. 
A number of nonpharmacologic or environmental interventions
may help some patients with dementia. Although limited
research data are available to support their use, clinical practice
suggests that improved symptoms may occur with behavior-,
stimulation-, emotion-, and cognition-oriented interventions
(APA 1997). Treatments directed at caregivers, including
supportive psychotherapy, support groups, and respite care, are
likely to be helpful to the caregiver and consequently may
benefit patients as well.
Cognitive decline
Specific symptoms targeted for treatment include cognitive
decline, psychosis and agitation, depression, and sleep
disturbances. For the treatment of cognitive decline, guidelines
recommend the use of AChEIs in patients with mild to moderate
Alzheimer’s disease (APA 1997; Doody et al 2001b; California
Workgroup 2002). Review of guideline recommendations for the
treatment of other specific target symptoms is beyond the scope
of this article.
Four AChEIs (tacrine, galantamine, rivastigmine, and donepezil)
are available. Tacrine is rarely used now because of hepatotoxicity
(Rabins 2004), so its characteristics are not reviewed in this
article. Other standard prescribed agents for the symptomatic
treatment of Alzheimer’s disease include memantine and
vitamin E. Memantine is an uncompetitive low-to-moderate
affinity  N-methyl-D-aspartate (NMDA) receptor antagonist that
regulates glutamate activity. It was approved in 2003 for the
treatment of cognition in moderate to severe Alzheimer’s disease
and, as it is relatively new to the market, memantine is not yet
included in existing evidence-based treatment guidelines. 
Vitamin E is recommended by guidelines as a treatment to delay
time to clinical worsening (APA 1997; Doody et al 2001b).
However, recent data (Petersen et al. 2005) conflict with evidence
in support of this indication (Tabet et al. 2000). 
The treatment effects and disadvantages of rivastigmine,
galantamine, memantine, and vitamin E are summarized in Table 4.
Unmet needs
Review of the characteristics of treatments included in Table 4
shows that various unmet needs remain for the symptomatic
treatment of mild to moderate Alzheimer’s disease. Although
the AChEIs rivastigmine and galantamine have demonstrated
consistent gains on cognitive and global scales compared
with placebo, these gains have been described as small on many
of the measures of effect (NICE 2005). However, in addition to
improvements, AChEI treatment can have a stabilizing
effect on cognitive and other symptoms (Giacobini 2000). The
clinical significance of this stabilizing effect requires further
investigation.
Randomized controlled trial (RCT) evidence on outcomes of
importance to patients and caregivers, such as quality of life and
time to institutionalization, is limited and largely inconclusive
(NICE 2005). There is no strong evidence that any of the
standard prescribed agents in Alzheimer’s disease alters the
course of the disease. Also, assessment of the adverse event
profile of the AChEIs suggests improved tolerability as another
area of unmet need. 
Donepezil is indicated for the symptomatic treatment of mild to
moderate Alzheimer’s disease and can be given once daily (Anon.
2005a). Generally, the initial dose is 5 mg/day, usually given at
night. After 4–6 weeks, if it is well tolerated, the dose is often
increased to 10 mg/day (see Dosage, administration, and
formulations), although both the 5 mg and 10 mg doses are
clinically effective. Donepezil has been available for 8–9 years and
a large number of publications from clinical trials and studies
conducted in community-based settings provide sources of
clinical evidence. 
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Stage of impairment Likely symptoms
Mild: patient has difficulties
limited to complex tasks such
as balancing a checkbook
Depression
Awareness of and frustration with deficits
Moderate: patient has difficulty
completing simple household
tasks
Depression
Development of psychotic symptoms such
as paranoia
Severe: patient requires
assistance with basic activities
of daily living such as personal
hygiene
Psychosis
Agitation
Profound: patient is terminal
and totally dependent
Bedbound with significant motor deficits
Feeding difficulties
Incontinence
Table 3 | Expected symptoms at each stage of impairment
(adapted from APA 1997)
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Drug Disease
severity
Drug class Outcome Disadvantages
Cognition ADL (function) Behavior/mood Disease
progression
Caregiver 
burden/time to
institutionalization
Rivastigmine
(high dose:
6–12 mg
daily)
Mild to
moderate
Cholinesterase
inhibitor
Significant
improvements on
ADAS-cog
scorea,b,  MMSE
scoreb, and
CIBIC-plus scaleb
Significant
improvement in
functiona,b
although one of
four RCTs
showed no
significant
difference from
placebo on PDSb
No benefit
reportedb
No evidence that
rivastigmine alters
the course of the
underlying
dementing
processc
Reduced caregiver
burden shown in
open-
label/observational
studiesb
Delayed time to
nursing home
placement shown
in open-label/
observational
studiesb
Significantly
higher numbers
of AEs vs
placebo at high
dose
(particularly
nausea and
vomiting). Led
to withdrawals
in studiesa,b
Administered
bidc
Galantamine Mild to
moderate
Cholinesterase
inhibitor
Significant
improvements on
ADAS-cog
scoreb,d.
Improvements in
CIBC-plus scale
in individual
studies, although
not statistically
significant with
pooled datab
Statistically
significantly less
deterioration than
those on placebo
for doses
between 16 and
32 mg/dayb
In one trial,
higher doses
(≥16 mg/day)
associated with
statistically
significant
slowing in
deterioration of
condition on NPI.
In two trials, no
significant
differenceb
No evidence that
galantamine alters
the course of the
underlying
dementing
processe
Pooled analysis of
two 6-month RCTs
suggested a
statistically
significant
decrease in overall
mean amount of
time caregivers
spent assisting
people with ADLb
Across the
RCTs, 2–27%
more
participants on
galantamine
suffered from
an AE
compared with
placebo.
Withdrawals
due to AEs
were
associated with
a loss of
6–44% of
galantamine
participantsb
Contraindicated
in patients with
severe hepatic
or renal
impairmente
Memantine Moderate
to severe
NMDA
receptor
antagonist
Statistically
significantly less
deterioration as
measured by the
SIB, but
deterioration as
measured by
MMSE not
significantly
different between
treatment and
control groupsb
Statistically
significantly less
deterioration as
measured by the
ADCS-ADL19/sev
scaleb
People receiving
memantine plus
donepezil had
statistically
significantly lower
NPI score
compared with
donepezil aloneb.
No significant
difference in trial
of memantine
aloneb
No evidence that
memantine
prevents or slows
neurodegeneration
in patients with
Alzheimer’s
diseasef
People taking
memantine
required
significantly less
caregiver timeb
Although the
frequency of
AEs was similar
in memantine
and control
groups, rate of
withdrawal due
to AEs was
relatively high in
the memantine
groupb
Not
recommended
in patients with
severe renal
impairmentf
Maintenance
dose
administered
bidf
continued overleaf…
Table 4 | Other standard prescribed agents for the symptomatic treatment of Alzheimer’s disease
 Clinical evidence for donepezil in
Alzheimer’s disease
Outcome measures
Alzheimer’s disease is characterized by deterioration in functional
ability, behavior, and cognition (see Disease overview). While
some scales quantify these patient-oriented outcomes by
assessing status in one or more of these domains, others attempt
to quantify a patient’s overall or global health state with respect to
Alzheimer’s disease (Wolfson et al. 2000). Table 5 lists the scales
that have been used most frequently in trials of donepezil in mild
to moderate Alzheimer’s disease. These scales have evidence of
reliability and validity, and have been used widely in studies of
other Alzheimer’s disease treatments (Wolfson et al. 2000).
However, it should be acknowledged that assessment via
different domains is somewhat artificial. For example, cognitive
function cannot be dissociated easily from ADLs. Also, the
relation of statistical significance to clinical significance is a
matter of debate in the field as is the clinical benefit of symptom
stabilization. For example, there is some opinion that a change in
ADAS-cog score of 3–4 points per year or change in MMSE of 
2 points per year is of detectable clinical significance (A. Wimo,
personal communication). Similarly, treatment may have no
apparent clinical benefit in that symptoms are only stabilized but
patient deterioration may follow cessation of treatment.
Global outcomes
There is level 1 evidence that donepezil is effective in improving
and maintaining global outcomes in the short to medium term
(12–24 weeks). There appears to be a clear treatment effect, since
these findings are consistent on three scales: the Clinical Global
Impression of Change (CGIC), Clinician’s Interview-Based
Impression of Change plus caregiver input (CIBIC-plus), and the
sum of boxes of the Clinical Dementia Rating (CDR-SB) scale
(Table 6). Also, there was significant benefit with both the
5 mg/day and 10 mg/day doses of donepezil, with no clear dose-
dependent differences. Six systematic reviews found statistically
significant differences from placebo in groups treated with
donepezil 5 or 10 mg/day in up to seven RCTs (Pryse-Phillips et
al. 2001; Clegg et al. 2002; Wolfson et al. 2002; Birks & Harvey
2003; Warner et al. 2004; NICE 2005; Table 6). In a meta analysis
of individual patient data from 10 RCTs (Whitehead et al. 2004),
the odds of improvement in CIBIC-plus scores was approximately
twice as great with donepezil 5 or 10 mg/day as with placebo at
12 and 24 weeks. 
This strong evidence is supported by a large open-label trial
conducted to investigate the efficacy of donepezil in a routine
setting in clinical practice (Froelich et al. 2004). On the CGIC scale,
nearly 80% of 186 patients showed an improvement or remained
stable at week 24 relative to baseline; 54% showed little to much
improvement, 25% were stable, and 17% were minimally worse. 
There is limited evidence to show that the effect of donepezil on
global outcomes is maintained beyond 24 weeks. One study of
longer duration was identified in a systematic review (Birks &
Harvey 2003). This 52-week, double-blind, parallel-group RCT
included 286 patients with mild to moderate Alzheimer’s disease
treated with donepezil 5 mg/day for 28 days and then 10 mg/day
(according to the clinician’s judgment) or placebo. Global
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…table continued
Drug Disease
severity
Drug class Outcome Disadvantages
Cognition ADL (function) Behavior/mood Disease
progression
Caregiver
burden/time to
institutionalization
Vitamin E Moderate Antioxidant Not possible to
interpret reported
resultsg
Not possible to
interpret reported
resultsg
Not possible to
interpret reported
resultsg
Limited evidence
that vitamin E
reduced mortality
and progression
of dementiag
No significant
difference in rate
of progression
between vitamin E
and placebo
over 3 years in
subjects with
MCIh
Limited evidence
that vitamin E
reduced
institutionalizationg
Excess of falls
in the vitamin E
group
compared with
placebo
requires further
evaluationg
Interaction with
other
medications
including
anticoagulants
aBirks et al. 2000.
bNICE 2005.
cExelon Prescribing Information (Anon. 2005c).
dLoy & Schneider 2004.
eReminyl Prescribing Information (Anon. 2005e).
fNamenda Prescribing Information (Anon. 2005d).
gTabet et al. 2000. 
hPetersen et al. 2005.
ADAS-cog, cognitive part of the Alzheimer’s Disease Assessment Scale; ADCS-ADL19, 19-item Alzheimer’s Disease Cooperative Study Activities of Daily Living inventory; ADL, activities of daily
living; AE, adverse event; bid, twice daily; CIBIC-plus, Clinician’s Interview-Based Impression of Change plus caregiver input; MCI, mild cognitive impairment; MMSE, Mini Mental State
Examination; NMDA, N-methyl-D-aspartate; NPI, Neuropsychiatric Inventory; PDS, Progressive Deterioration Scale; RCT, randomized controlled trial; SIB, Severe Impairment Battery.203
outcomes were assessed using the Gottfries–Brane–Steen (GBS)
scale. At 52 weeks, the mean difference from placebo was –6.01,
an improvement with borderline statistical significance (P=0.05). 
Cognition
There is strong evidence that donepezil treatment improves
cognition and that these improvements are maintained in the
short to medium term (12–24 weeks) (Table 6). A meta analysis
revealed benefits associated with donepezil 5 and 10 mg/day
compared with placebo as shown by improvements in ADAS-cog
MMSE scores at 12 and 24 weeks (Birks & Harvey 2003). Another
meta analysis of trials lasting 12–24 weeks showed weighted
mean differences in ADAS-cog of –2.51 for 5 mg/day and –3.01
for 10 mg/day donepezil compared with placebo (NICE 2005).
This improvement in ADAS-cog score is broadly in line with
results reported in other systematic reviews (Pryse-Phillips et al.
2001; Wolfson et al. 2002; Birks & Harvey 2003; Warner et al.
2004) and in a meta analysis of individual patient data
(Whitehead et al. 2004). 
The evidence in favor of improved cognition in the short to
medium term conflicts with the results of a small RCT (Hegerl et
al. 2003). A 12-week study of donepezil 5 or 10 mg/day reported
no significant improvement in ADAS-cog score versus placebo,
although this trial included only 40 patients (Hegerl et al. 2003). In
another more recent but larger study (n=153), patients received
donepezil 5 mg/day for 6 weeks, then 10 mg/day for 18 weeks
(Seltzer et al. 2004). At 24 weeks, there were significant
improvements in both MMSE and ADAS-cog versus placebo
(P=0.03 and P=0.008, respectively). 
The effect of donepezil on cognition appears to be maintained
long term. A meta analysis showed that improvements in MMSE
score are maintained at 52 weeks with donepezil 10 mg/day
compared with placebo (weighted mean difference 1.84 points,
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Outcome Measure Description Scoring
Global Clinical Global Impression of Change (CGIC),
Clinician’s Interview-Based Impression of
Change (CIBIC)
Measures general physical and mental
condition of patients, including functional ability
with respect to ADL, cognition, behavior, mood.
CIBIC-plus includes caregiver input
Seven-point scale to measure improvement
(1=very much improved, 7=very much worse)
Clinical Dementia Rating-sum of boxes
(CDR-SB)
Measures cognitive performance in six areas:
memory, orientation, judgment/problem
solving, community affairs, home/hobbies,
personal care
Each category scored on five-point scale of
impairment (0=none, 0.5=questionable, 1=mild,
2=moderate, 3=severe). The sum of ratings
(0–18) provides the CDR-SB
Cognitive Mini Mental State Examination (MMSE) Includes 11 questions on orientation, memory,
concentration, language, and praxis
Scale ranges from 0 to 30, a higher score
indicating less impairment
Cognitive part of the Alzheimer’s Disease
Assessment Scale (ADAS-cog)
Includes 11 items on orientation, memory,
language, and praxis
Scale ranges from 0 to 70, a higher score
indicating greater dysfunction
Functional Progressive Deterioration Scale (PDS) Examines ADL and instrumental ADL in
11 areas, e.g. extent to which patient can
leave immediate neighborhood, use of familiar
household implements, involvement in family
finances and budgeting, self-care, and routine
tasks
Scale ranges from 0 to 100, a higher score
indicating better functioning
Instrumental Activities of Daily Living (IADL) Measures competence in complex ADL,
including telephoning, shopping, food
preparation, housekeeping, laundering, use of
transportation, use of medicine, ability to
handle money
Each behavioral area is scored 1 or 0. Higher
score indicates better performance
Katz activities of daily living (ADL) index Assesses ability to perform ADL independently
in six functions of bathing, dressing, toileting,
transferring, continence, and feeding
Scored yes/no for independence in each
function. Total score of 6 indicates full function,
2 or less indicates severe functional impairment
Behavior/
mood
Neuropsychiatric Inventory (NPI) Evaluates 10 items: delusions, hallucinations,
dysphoria, anxiety, agitation, euphoria, apathy,
irritability, disinhibition, aberrant motor behavior
(pacing and rummaging). Two more items may
also be assessed – night-time behavior, and
changes in appetite and eating behaviors
Frequency of behavioral disturbances rated on
four-point scale, severity rated on three-point
scale. Higher total score indicates more
behavioral problems
Table 5 | Scales used most frequently in trials of donepezil in mild to moderate Alzheimer’s disease (Katz et al. 1963;
Wolfson et al. 2000; Birks & Harvey 2003)
 P=0.006) (Birks & Harvey 2003). In the AD2000 RCT of 565
community-resident patients, improvements in MMSE score were
maintained beyond 52 weeks with donepezil 5 or 10 mg/day
(Courtney et al. 2004). There was a significant improvement in
average score versus placebo over 2 years, albeit a modest one
(0.8 points, P<0.0001), with no significant difference between
dose groups. Interpretation of results from this study, however,
must take into account concerns regarding its recruitment rate
and methodology (Akintade et al. 2004; Holmes et al. 2004a). Only
one fifth of the planned number of patients was recruited and high
discontinuation rates during the study are likely to have
detrimentally affected the power of the study. Also, the study had
repeated wash-out periods, and 16% of patients also had
vascular dementia. 
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Design Treatment,
dose, duration
Measure Reference
CGIC/CIBIC-plus CDR-SB MMSE ADAS-cog
Systematic
review/
meta
analysis
DPZ 5 or
10 mg/day,
12–24 wk
SD vs PL (meta analysis):
–2.51 WMD from BL
(5 mg/day, 3 studies);
–3.01 WMD from PL
(10 mg/day, 3 studies);
–2.88 MD from BL (dose
NR, 1 study)
NICE 2005
DPZa SD vs PL in change from
BL (7 studies)
Trends towards improved
scores vs PL (8 studies)
Systematic
review
DPZ 10 mg/day,
24 wk
OR for global improvement
in CIBIC-plus: 2.2 
SD vs PL: –2.9  Warner
et al. 2004
Meta
analysis
DPZ, 5 or
10 mg/day,
12, 24 wk
OR of improvement vs PL
on CIBIC-plus: 5 mg/day,
12 wk, 1.8; 10 mg/day, 12
wk, 1.9; 5 mg/day, 24 wk,
1.9; 10 mg/day, 24 wk, 2.1
(all P≤0.001)
SD vs PL: 5 mg/day,
12 wk, –2.1; 10 mg/day,
12 wk, –2.5; 5 mg/day,
24 wk, –2; 10 mg/day,
24 wk, –3.1 (all P<0.001) 
Whitehead
et al. 2004
Meta
analysis
DPZ 5 or
10 mg/day,
12, 24, 52 wk
CIBIC-plus: SD vs PL:
5 mg/day, 12 wk (P=0.005);
10 mg/day, 12 wk
(P=0.0001); 
5 mg/day, 24 wk
(P≤0.00001);
10 mg/day, 24 wk
(P≤0.0001)
SD vs PL: 10 mg/day,
12 wk (P=0.05);
5 mg/day, 24 wk
(P≤0.00001);
10 mg/day, 24 wk
(P≤0.00001) 
SD vs PL: 5 mg/kg,
12 wk (P≤0.00001);
10 mg/day, 12 wk
(P≤0.00001); 5 mg/day,
24 wk (P=0.0004);
10 mg/day, 24 wk
(P≤0.00001); 10 mg/day,
52 wk (P=0.006)
SD vs PL, all P≤0.00001:
5 or 10 mg/day,
12 or 24 wk 
Birks & Harvey
2003b
Systematic
review
DPZ 5 or
10 mg/day, NR
SD vs PL: P<0.05
(6 studies)
SD vs PL: 5 mg/day,
P≤0.01 (4 studies);
10 mg/day, P<0.001
(2 studies)
Wolfson
et al. 2002
Systematic
review
DPZ 5 or
10 mg/day, NR
SD vs PL for global
outcomes in 5 of 6 RCT
(CDR included in 1 study)
SD vs PL in 2 of 3 RCT SD vs PL in 6 of 6 RCT  Clegg et al.
2002
Systematic
review
DPZ 5 mg/day,
12 wk
NSD vs PL for CGIC
functional, QOL, disease
severity parameters
(1 study)
SD vs DPZ 1 mg/day:
adjusted mean change
from BL 2 (1 study). NSD
vs PL
SD vs PL: adjusted mean
change from BL –2.5
(1 study)
Pryse-Phillips
et al. 2001
DPZ 5 or
10 mg/day, NR
SD vs PL (improvement) at
12, 18, 24 weeks (1 study)
DPZ 10 mg/day,
12 wk
SD vs PL for CIBIC-plus:
MD 0.4 (P<0.008) (1 study)
SD vs PL: MD 1.3
(P<0.004) (1 study)
SD vs PL: MD 3.1
(P<0.001) (1 study)
DPZ 5 mg/day,
24 wk
SD from BL (1 study)
aDose and duration not reported. 
bAssessment included patients with mild, moderate, or severe dementia due to Alzheimer’s disease.
ADAS-cog, cognitive part of the Alzheimer’s Disease Assessment Scale; BL, baseline; CDR-SB, the sum of boxes of the Clinical Dementia Rating scale; CGIC, Clinical Global Impression of
Change; CIBIC-plus, Clinician’s Interview-Based Impression of Change plus caregiver input; DPZ, donepezil; MD, mean difference; MMSE, Mini Mental State Examination; NR, not reported;
NSD, no statistically significant difference; OR, odds ratio; PL, placebo; QOL, quality of life; RCT, randomized controlled trial; SD, statistically significant difference; wk, week; WMD, weighted
mean difference.
Table 6 | Effects of donepezil on global outcomes and cognition (level 1 evidence)
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Some level 3 and 4 evidence also shows that donepezil treatment
reduces the rate of decline in MMSE score. In an open-label,
matched control study, 205 AChEI-treated and 218 untreated
Alzheimer’s disease patients were compared over 1 year (Doody
et al. 2001c). The decline in MMSE score was significantly less in
53 patients treated with donepezil (dose not specified) than in the
untreated group (–1.5 vs –3.7 points, P=0.007). In a 3-year
retrospective chart review (level 4 evidence) of patients given
combination therapy of donepezil (≥5 mg/day) and vitamin E
(≥1000 U/day) (Klatte et al. 2003), average MMSE values
decreased at 1, 2, and 3 years (average cumulative change –1.43,
–4.05, and –6.27, respectively). The authors report that the
decline was significantly slower than in untreated patients
included in the 1986–1996 Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) database. However, the numbers of
patients treated long term in this study were small (40 had 1-year,
38 had 2-year, and 22 had 3-year follow-up). Other level 3
evidence shows decreases in MMSE score from baseline at 1 year
or 18 months but, as these studies did not include untreated
control groups, it is difficult to put these data into context (Saine
et al. 2002; Blasko et al. 2004; Requena et al. 2004).
Donepezil appears to be at least as effective as other treatments
of cognitive function, such as rivastigmine, galantamine, tacrine,
and vitamin E (Table 7). One systematic review reported no
significant differences in cognitive function (MMSE or ADAS-cog)
between donepezil and rivastigmine (12-week open-label study)
or galantamine (52 week RCT) (Warner et al. 2004). In an open-
label trial of donepezil and rivastigmine, there was no significant
between-group difference in change from baseline MMSE score
(Mossello et al. 2004). Similarly, there were no significant
differences in MMSE or ADAS-cog scores in an open-label study
of patients treated with donepezil, rivastigmine, or galantamine
(Aguglia et al. 2004). A difference was observed between tacrine-
and donepezil-treated groups in another open-label study
(Doody et al. 2001c); the difference from the untreated group was
significant in donepezil-treated patients (P=0.007) but not in the
tacrine group (P=0.33). One RCT showed significant differences
between donepezil- and vitamin E-treated patients in favor of
donepezil in MMSE and ADAS-cog scores, the greatest
differences seen in patients with fluctuating cognition (Onofrj et
al. 2003). However, only 23 patients were included in this trial and
the randomized part of the study was of short duration (30 days). 
Function
There is level 1 evidence that donepezil treatment produces
significantly improved or less deterioration in functional ability than
placebo (Clegg et al. 2002; Wolfson et al. 2002; Birks & Harvey
2003; Warner et al. 2004; Table 8). Although this finding was not
statistically significant in all short-term trials (NICE 2005), there is
evidence of significant benefit with long-term donepezil treatment.
In a 1-year trial of donepezil 10 mg/day, there was significant
benefit versus placebo in the primary endpoint, time to clinically
evident decline in function (Wolfson et al. 2002; Birks & Harvey
2003; Warner et al. 2004). One systematic review reports that, in
this study, donepezil delayed median time to primary endpoint by
5 months compared with placebo (Warner et al. 2004).
Level of
evidence
Design Treatment, dose,
duration
Measure Reference
MMSE ADAS-cog
1 Systematic review DPZ 5–10 mg/day, 12 wk NSD vs RIV 1.5–6 mg bid (MD –0.15)
(1 study)
Warner et al.
2004
DPZ ≤10 mg/day, 52 wk NSD vs GAL ≤24 mg/day in change
from BL: DPZ –1.58, GAL –0.52 
NSD vs GAL ≤24 mg/day in change
from BL: DPZ –3.43, GAL –2.22
2 RCT DPZ 10 mg/day or
vitamin E 2000 IU/day,
30 days (FC, n=11;
NFC, n=12)
FC, SD vs vitamin E: 21.33 vs 18.24
(P=0.001)
NFC, SD vs vitamin E: 20.05 vs 18.55
(P=0.03)
FC, SD vs vitamin E: 29.28 vs 32.31
(P=0.003)
NFC, NSD vs vitamin E (P=0.06)
Onofrj et al.
2003
3 OL DPZ 5–10 mg/day
(n=256). RIV 6–12 mg/day
(n=132), 9 mo
Overall, SD vs BL: 0.7 at 3 mo
(P<0.001) and –0.6 (P=0.006) at 9 mo.
NSD between DPZ and RIV groups
Mossello et al.
2004
3 OL, part R DPZ 10 mg/day (n=70) or
RIV 3–6 mg bid (n=121)
or GAL 8 mg bid (n=51),
6 mo
NSD vs RIV (0.15 vs 0.03) or GAL (0.15
vs –1.18) in change from BL at 6 mo
NSD vs RIV (0.17 vs –1.29) or GAL
(0.17 vs –0.05) in change from BL at
6 mo
Aguglia et al.
2004
3 OL, matched
control
DPZ, NR (n=53) or TAC,
NR (n=128), 1 y.
Untreated control (n=218)
SD vs control in change from BL: –1.5
vs –3.7 (P=0.007)
TAC, NSD vs control in change from
BL: –2.8 vs –3.7 (P=0.33)
Doody et al.
2001c
ADAS-cog, cognitive part of the Alzheimer’s Disease Assessment Scale; bid, twice daily; BL, baseline; DPZ, donepezil; FC, fluctuating cognition; GAL, galantamine; MD, mean difference;
MMSE, Mini Mental State Examination; mo, month; NFC, nonfluctuating cognition; NR, not reported; NSD, no statistically significant difference; OL, open label; R, randomized; RCT,
randomized controlled trial; RIV, rivastigmine; SD, statistically significant difference; TAC, tacrine; wk, week; y, year. 
Table 7 | Effects of donepezil on cognition
 Two RCTs also found significant differences in favor of donepezil
over placebo in maintaining or improving function in the long term
(Table 8; Wimo et al. 2003b; Courtney et al. 2004). In one trial,
subdomain analysis of the PDS at week 52 showed benefits with
donepezil 5 or 10 mg/day treatment in 9 of 10 domains (Wimo et
al. 2003b). The difference from placebo reached statistical
significance for the telephone (P=0.009), memory (P=0.003), and
self-care (P=0.042) items. In the same study, significantly fewer
patients in the donepezil group deteriorated in individual IADL
items at week 52 compared with placebo-treated patients. In the
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Level of
evidence
Design Treatment,
dose,
duration
Measure Reference
PDS IADL Katz ADL Other
1 Systematic
review
DPZ
10 mg/day,
52 wk
DPZ delayed median
time to “clinically evident
functional decline” by
5 mo vs PL (median
357 days DPZ,
208 days PL)
Warner et al.
2004 
1 Systematic
review
DPZ 5 or
10 mg/day,
12, 24, 52 wk
SD vs PL at 52 wk:
P=0.0004 (10 mg/day)
SD vs PL at 12 and
24 wk: 10 mg/day,
12 wk, P=0.01;
10 mg/day, 24 wk,
P=0.0008 
SD vs PL at 54 wk in
time to clinically evident
decline in function
(10 mg/day, P=0.001)
Birks &
Harvey
2003a
1 Systematic
review
DPZ
10 mg/day,
52 wk
Higher proportion of
patients had no
“clinically evident
functional decline” at
48 wk vs PL (51 vs 35%)
Wolfson et al.
2002
1 Systematic
review
DPZ 5 or
10 mg/day,
12, 24 wk
1 of 2 RCTs showed
significant beneficial
effects (1 study used
IDDD)
Clegg et al.
2002
2 MC, DB,
RCT
DPZ 5 or
10 mg/day
(n=283) or PL
(n=283), ≤3 y
SD vs PL for BADLS
(1; P=0.0004) over 2 y
Courtney et
al. 2004
2 MC, DB,
RCT
DPZ 5 or
10 mg/day
(n=142) or PL
(n=144), 1 y
Benefit vs PL for 9 of
10 domains; SD for
telephone, memory, and
self-care (all P<0.05)
SD vs PL for
deterioration in
individual IADL items
(overall P=0.025)
Wimo et al.
2003b 
3 OL, part R DPZ
10 mg/day
(n=70), or RIV
3–6 mg bid
(n=121), or
GAL 8 mg bid
(n=51), 6 mo
NSD at 6 mo: change
from BL –0.42 (RIV),
–0.58 (DPZ), –0.75
(GAL)
NSD at 6 mo: change
from BL –0.01 (RIV),
–0.44 (DPZ), –0.86
(GAL)
Aguglia et al.
2004
3 OL DPZ
5–10 mg/day
(n=256), or RIV
6–12 mg/day
(n=132), 9 mo
NSD between DPZ or
RIV
SD vs RIV at 9 mo
(–0.3 vs –0.7, P=0.02)
Mossello et
al. 2004
3 MC, OL DPZ 5 or
10 mg/day
(n=200), 24 wk
Patients remained
stable (minor
deteriorations
observed, 0.38–0.68)
Patients remained
stable (minor
deteriorations
observed, 0.55–0.61)
Santens &
Ventura 2003
3 OL DPZ 5 or
10 mg/day
(n=24), 12 mo
Change in TFLS score at
BL: 3.25 at 3 mo, –0.37
at 12 mo
Saine et al.
2002
aAssessment included patients with mild, moderate, or severe dementia due to Alzheimer’s disease.
ADL, activities of daily living; BADLS=Bristol Activities of Daily Living Scale; bid, twice daily; BL, baseline; DB, double blind; DPZ, donepezil; GAL, galantamine; IADL, Instrumental Activities of
Daily Living; IDDD, Interview for Deterioration in Daily living in Dementia; MC, multicenter; mo, month; NSD, no statistically significant difference; OL, open label; PDS, Progressive Deterioration
Scale; PL, placebo; R, randomized; RCT, randomized controlled trial; RIV, rivastigmine; SD, statistically significant difference; TFLS, Texas Functional Living Scale; wk, week; y, year.
Table 8 | Effects of donepezil on function
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AD2000 study, the donepezil group had better Bristol Activities of
Daily Living Scale (BADLS) scores at all timepoints after 12 weeks
(Courtney et al. 2004); the average difference was 1 point better
with donepezil than with placebo (P=0.0004), and efficacy was
maintained over 2 years. There was no significant difference
between the 5 and 10 mg/day dose groups (P=0.24).
This evidence is supported by level 3 evidence showing that
patients’ function remained relatively stable after up to 12 months
of donepezil 5 or 10 mg/day treatment (Saine et al. 2002; Santens
& Ventura 2003; Aguglia et al. 2004; Mossello et al. 2004; Table 8).
Also, donepezil appears to be at least as effective in maintaining
function as other treatments, such as rivastigmine and
galantamine. In a comparative study of donepezil, rivastigmine,
and galantamine, there were no significant differences between
groups in IADL and ADL at 6 months (Aguglia et al. 2004). Another
trial found no significant difference between donepezil and
rivastigmine groups in IADL score changes over time but a
significantly lower decline in ADL with donepezil at 9 months
(P=0.02) (Mossello et al. 2004).
Behavior/mood
There is some level 1 evidence showing that donepezil has an
effect in improving or limiting deterioration in behavior or mood in
the short to medium term (Birks & Harvey 2003; NICE 2005; Table
9). This is supported by level 2 evidence of significant benefit
compared with placebo (Holmes et al. 2004b; Table 9). This trial
began with an open-label phase of treatment with donepezil
5 mg/day for 6 weeks followed by 10 mg/day for a further 6 weeks.
At 12 weeks, total NPI and NPI distress scores were significantly
lower compared with baseline. Further improvements in NPI and
NPI distress scores were observed in the medium term during the
subsequent 12-week randomized part of the study, and these
improvements were significant in comparison with placebo. 
This evidence is supported by two open-label trials that showed
improvement or stabilization of NPI scores with donepezil treatment
in the short to medium term (Santens & Ventura 2003; Tanaka et al.
2004). In a study of 70 patients, the majority showed no behavioral
change after 12 weeks (≤3-point decrease or increase in total NPI
score), and nearly one third had improved symptoms (≥4-point
reduction) (Tanaka et al. 2004). In a study performed in a routine
clinical setting, Santens and Ventura (2003) found no significant
change in overall behavior score in 200 patients after 6 months of
treatment with donepezil 5 mg/day or 10 mg/day. The NICE
Assessment Group also comments that, in observational studies,
use of donepezil appeared to show benefit on improvements in
social behavior assessed by the caregiver diary (NICE 2005).
No evidence was found showing that donepezil improves or
maintains behavioral symptoms long term (beyond 6 months).
Disease progression
Disease progression has been assessed by monitoring both
patient- and disease-oriented outcomes. Patient-oriented
outcomes include progression of disability and death rate, while
disease-oriented outcomes include regional cerebral blood flow
(rCBF), 123I quinuclidinyl benzilate (QNB) uptake in the brain,
quantitative electroencephalogram (qEEG), and the degree of
hippocampal atrophy.
The results of two RCTs provide evidence (level 2) of an effect by
donepezil on disease progression in terms of patient-oriented
outcomes (Courtney et al. 2004; Petersen et al. 2005). In the
AD2000 study, there were no significant benefits with donepezil
compared with placebo in progression of disability at 3 years or
numbers of deaths (Courtney et al. 2004). In a study of patients
with mild cognitive impairment, the donepezil group (10 mg/day)
had reduced likelihood of progression to Alzheimer’s disease at
12 months in comparison with placebo (P=0.04), but this
difference was not maintained at 3 years (Petersen et al. 2005). 
Lower level evidence of an impact on mortality rate is available
from a retrospective matched cohort study using a database of
nursing home residents in six US states (Gasper et al. 2005). A
total of 5423 residents treated with donepezil were compared with
5423 nonusers of donepezil. Based on Cox proportional hazards
models, donepezil users showed a lower mortality rate than
nonusers [hazard rate ratio (HRR) 0.89]. This survival advantage
remained after adjusting for sociodemographic factors, other
psychotropic drugs, and comorbid conditions (HRR 0.9).
There is some level 2 evidence that donepezil may have an effect
on the disease-oriented outcomes, rCBF (Nakano et al. 2001),
123I QNB uptake in the brain (Kemp et al. 2003), and hippocampal
volume (Krishnan et al. 2003; Table 10). Treatment with donepezil
5 mg/day reduced the decline in rCBF, possibly indicating
preservation of functional brain activity (Nakano et al. 2001).
Kemp et al. (2003) demonstrated better uptake of 123I QNB in
patients who had received donepezil 10 mg/day for 4 months
than in those on placebo; the authors suggest this shows
cholinergic treatment may have a neuroprotective role. At the end
of a 24-week study of patients treated with donepezil 10 mg/kg or
placebo, donepezil-treated patients had significantly smaller
mean decreases in total (P<0.01) and right (P<0.02) hippocampal
volumes (Krishnan et al. 2003). Again, these data suggest a
possible neuroprotective effect of donepezil in Alzheimer’s
disease.
This evidence is supported by several 1-year, open-label trials that
included matched control groups (Nobili et al. 2002; Rodriguez et
al. 2002; Hashimoto et al. 2005; Table 10). In one study, 54 patients
who received donepezil 5 mg/day underwent MRI twice at a 1-year
interval (Hashimoto et al. 2005). The results were compared with
those from a matched control group of 93 untreated patients. The
mean annual rate of hippocampal atrophy in the treated group was
significantly lower than in the control group (3.82 vs 5.04%,
P=0.008), suggesting a neuroprotective effect with donepezil.
Similarly, rCBF was preserved in 25 patients undergoing donepezil
treatment (5 mg/day) for 1 year but was reduced in 13 untreated
patients (Nobili et al. 2002). Long-term treatment with donepezil
5 mg/day has also been shown to lead to lesser deterioration of
qEEG in comparison with an untreated group of patients
(Rodriguez et al. 2002).
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disease progression, but further RCT evidence is needed to
confirm if these translate into clinical effects reflecting disease
modification.
Time to institutionalization
There is limited and conflicting evidence that donepezil treatment
has an effect on the patient-oriented outcome of delayed time to
institutionalization (Table 10). The AD2000 RCT found no
significant difference between the donepezil group and placebo
group in institutionalization at 1 or 3 years (Courtney et al. 2004).
However, the small number of patients remaining in this study at
3 years must be taken into account (n=57 and 60 in donepezil and
placebo groups, respectively). 
Lower level evidence (level 3) from two large studies supports a
delay in or reduced risk of nursing home placement among
patients treated with donepezil (Geldmacher et al. 2003;
Beusterien et al. 2004), particularly those who complied well with
their treatment regimen (Geldmacher et al. 2003; Table 10). In a
smaller study, 135 pairs of patients with probable Alzheimer’s
disease were matched to compare those on AChEIs (130 on
donepezil) with untreated patients (Lopez et al. 2005). Within 
2 years of study entry, 16% of untreated patients were in a
nursing home, compared with 1% of treated patients (relative risk,
0.06; 95% confidence interval 0.008, 0.48; P=0.001). This
significant difference in nursing home admissions was maintained
at 3 years (50 vs 11%, P<0.001). These results are supported by
a systematic review which notes that, in observational studies,
use of donepezil appeared to show a benefit on delayed time to
nursing home placement (NICE 2005).
Quality of life
Evidence is divided on whether donepezil improves patients’
quality of life (Table 11). The systematic reviews reported mixed
results, with the most recent (conducted by the NICE
Assessment Group) pointing to improvements, no change, and
worsening quality of life in three RCTs, and the impact of the
dose used for donepezil being unclear (NICE 2005). Only one
open-label study was identified beyond those covered in the
systematic reviews, and this study did not use a validated
quality-of-life scale for dementia (Frölich et al. 2002). Instead,
investigators were asked to answer the question, “How did
therapy with donepezil influence the quality of life of the patient
and/or his family over the observation period?”, offering three
possible outcomes: improved, unchanged, or worsened. After 
3 months of treatment, quality of life was judged as “improved”
in 70% of patients overall. 
Caregiver burden
There is some evidence that donepezil lessens caregiver burden in
terms of caring time spent each day (Table 11). However, only one
systematic review mentions this aspect (Birks & Harvey 2003),
reporting that caregiver stress was assessed in one study, but the
results were reported without any measure of precision. This review
also highlights the results of an RCT, which showed significant
benefit with donepezil treatment in comparison with placebo in time
spent each day by the caregiver assisting with ADL. 
Level 2 evidence from RCTs is conflicting (Courtney et al. 2004;
Wimo et al. 2004). At 12 months, Wimo et al. (2004) reported a
significant difference in caring time relative to baseline between
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Level of
evidence
Design Treatment,
dose, duration
Effect on NPI score Reference
1 Systematic
review
DPZa DPZ may have some effect in improving or limiting further deterioration on the NPI scale vs PL, at
least in the short term (4 studies)
NICE 2005
1 Systematic
review
DPZ 10 mg/day,
12 and 24 wk
SD vs PL at 24 wk (MD –4.42, P=0.01) but not at 12 wk (1 study) Birks &
Harvey 2003b
2 RCT DPZ 10 mg/day
(n=41) or PL
(n=55), 12 wk
SD vs PL for improvement in NPI (–2.9 vs 3.3, P=0.02) and NPI distress scores (–2 vs 1, P=0.01) Holmes et al.
2004b
3 OL DPZ 5 then
10 mg/day
(n=134), 12 wk
SD vs BL for improvement in NPI (13 vs 22; P<0.0001) and NPI distress scores (7.9 vs 13.5,
P<0.0001). All domains of NPI improved (except elation) (P<0.005)
Holmes et al.
2004b
3 OL DPZ 5 mg/day
(n=70), 12 wk
30% responded (≥4-point reduction in NPI), 60% showed no change, 10% worsened (≥4-point
increase in NPI)
Tanaka et al.
2004
3 MC, OL DPZ 5 or
10 mg/day
(n=200), 24 wk
No change from BL after ≥140 days DPZ  Santens &
Ventura 2003
aDose and duration not reported.
bAssessment included patients with mild, moderate, or severe dementia due to Alzheimer’s disease.
BL, baseline; DPZ, donepezil; MC, multicenter; MD, mean difference; NPI, Neuropsychiatric Inventory; OL, open label; PL, placebo; RCT, randomized controlled trial; SD, statistically significant
difference; wk, week. 
Table 9 | Effects of donepezil on behavior/mood as assessed by the Neuropsychiatric Inventory
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Level of
evidence
Design Treatment,
dose, duration
Disease progression measurement Time to
institutionalization
Reference
rCBF qEEG Other
1 Systematic
review
DPZa In observational studies,
DPZ appeared to show
benefit on delayed time
to NHP
NICE 2005
2 MC, DB,
RCT
DPZ 5 or
10 mg/day
(n=283) or PL
(n=283), ≤3 y
NSD vs PL for progression
of disability or numbers of
deaths
NSD vs PL (42 vs 44%
at 3 y, P=0.4)
Courtney
et al. 2004
2 MC, DB,
RCT
DPZ 10 mg/day
(n=253), vitamin E
(n=257), or PL
(n=259), 3 y
SD (P=0.04) in favor of
DPZ vs PL for disease
progression at 12 mo
(16 vs 38 pts) but not
after 3 y
Petersen
et al. 2005
2 DB, RCT DPZ 10 mg/day
(n=6) or PL
(n=6), 4 mo
123I QNB uptake better
preserved in DPZ- than in
PL-treated pts
Kemp et al.
2003
2 RCT DPZ 10 mg/day
(n=34) or PL
(n=33), 24 wk
SD in favor of DPZ vs PL
for mean decreases in
total (P<0.01) and right
(P<0.02) hippocampal
volume
Krishnan
et al. 2003
2 RCT DPZ 5 mg/day
(n=15) or PL
(n=20), 12 mo
SD vs PL in
preservation of rCBF
Nakano et al.
2001
3 Retrospect-
ive, matched
control
DPZ 5 or
10 mg/day
(n=5423);
untreated control
(n=5423), NR
DPZ group had lower
mortality rate than control
(HRR 0.89; 95% CI 0.83,
0.95). With adjustment for
confounding variables,
HRR 0.9 (95% CI 0.84,
0.96)
Gasper et al.
2005
3 OL,
matched
control
DPZ 5 mg/day
(n=54), 1 y;
untreated control
(n=93)
SD (P=0.008) vs control in
mean annual rate of
hippocampal volume loss
(3.82 vs 5.04%)
Hashimoto
et al. 2005
3 OL,
matched
control
DPZ 5 mg/day
for 11 ± 2.6 mo
(n=25); untreated
control (n=13)
In control group, SD
vs BL in rCBF
reduction. NSD in
DPZ group
Nobili et al.
2002
3 OL,
matched
control
DPZ 5 mg/day
(n=20) for 1 y;
untreated control
(n=11)
SD vs control in
MMSE (P<0.01)
and qEEG ratio
(P<0.01)
Rodriguez
et al. 2002
3 OL,
matched
control
DPZ, NR
(n=130), TAC,
NR (n=22), RIV,
NR (n=6), control
(n=135), follow-
up at 2 and 3 y
At 2 y, NHP 16% in
control vs 1% in treated
group (relative risk, 0.06;
P=0.001). At 3 y, 50 vs
11% (P<0.001)
Lopez et al.
2005
3 Retrospect-
ive analysis
DPZ, NR
(n=3864), RIV,
NR (n=1181),
control (n=517)
from BL (April 1,
2000) to NHP or
June 30, 2002 
4.4, 3.7, 11% of DPZ,
RIV, control subjects had
an NHP. NSD in risk of
NHP between DPZ and
RIV 
Beusterien
et al. 2004
continued overleaf…
Table 10 | Effects of donepezil on disease progression and time to institutionalization
 caregivers of donepezil-treated patients and caregivers of
placebo-treated patients of 1.1 h per day (P=0.03) (Wimo et al.
2004). In the AD2000 study, however, there were no significant
differences between the donepezil and placebo groups in any of
the caregiver parameters assessed (Courtney et al. 2004).
Further evidence suggesting a positive effect of donepezil on
caregiver burden comes from an open-label study in which
a self-administered, nationwide survey was used to match
274 caregivers of patients treated with donepezil to 
274 caregivers of untreated patients (Fillit et al. 2000). There were
significant differences between the groups in favor of donepezil
on the total difficulty scale (P=0.004), mainly due to differences in
assisting with walking (P≤0.001), providing emotional support
(P≤0.001), and managing behavioral problems (P=0.05). However,
there was no significant difference on the demand scale, which
measured the frequency of engaging in caregiving activities.
Tolerability
Poor drug tolerability is a serious concern in patients with
Alzheimer’s disease because of their advanced age and the high
prevalence of comorbid disease (Jackson et al. 2004). There is
level 1 evidence that donepezil is well tolerated and that adverse
events are usually cholinergic in nature (e.g. nausea, vomiting,
and diarrhea) and generally mild and transient (Clegg et al. 2002;
Wolfson et al. 2002; Birks & Harvey 2003; Warner et al. 2004;
Whitehead et al. 2004). Adverse events were recorded more often
in patients receiving donepezil than in those on placebo, and
there was an increased frequency with the higher dose of
10 mg/day (Birks & Harvey 2003; Whitehead et al. 2004; NICE
2005). Also, in the short term, more patients discontinued
donepezil treatment on account of adverse events than in placebo
groups. However, when treatment was longer than 12 weeks,
there was no evidence of a difference in numbers of patients
leaving the trials (Birks & Harvey 2003). 
A dose-dependent effect was confirmed in a meta analysis of
individual patient data from 10 RCTs (Whitehead et al. 2004). In
821 patients treated with donepezil 5 mg/day, only the incidence
of diarrhea was significantly higher in the donepezil group in
comparison with placebo (7 vs 4%, P<0.01). Among patients
treated with donepezil 10 mg/day (n=662), nausea (21%), diarrhea
(16%), headache (13%), insomnia (12%), vomiting (11%),
dizziness (8%), and pain (8%) (all P<0.01), and rhinitis (8%,
P<0.05) had significantly higher incidences compared with
placebo. However, the authors note that, of the adverse events
that occurred in at least 5% of patients, only diarrhea, nausea,
vomiting, and dizziness were considered related to study
medication in a majority of patients in each treatment group. Also,
most adverse events were mild, only occasionally moderate in
intensity, and generally transient in nature.
In the larger open-label studies (n>100), reported incidences of
adverse events ranged widely, from 9.3 to 96% (Table 12).
Gastrointestinal and psychiatric/neurologic adverse events were
reported most frequently, and the frequency of discontinuations
due to adverse events was less than 10% in most studies. In the
two largest studies conducted, donepezil treatment was regarded
as well tolerated, despite high concomitant medication use and
extensive comorbidity among the patient groups (Hager et al.
2003; Relkin et al. 2003). However, there was inconsistency in
incidences of adverse events; while Relkin et al. (2003) reported
incidences in line with those in RCTs, Hager et al. (2003) reported
considerably lower incidences. The latter authors suggest that
this may be explained by the naturalistic nature of the
postmarketing surveillance study, where the treating physician is
likely to not ask for adverse events as specifically as in a
controlled trial. Also in this study, most patients whose donepezil
dose was increased to 10 mg were able to tolerate the treatment
as well as those who continued on the 5 mg dose (Hager et al.
2003). In contrast, Relkin et al. (2003) found the occurrence of
cholinergic-induced adverse events appeared to be directly
related to the timing of dose increase from 5 to 10 mg/day at 
4 weeks (Relkin et al. 2003).
The tolerability profile of donepezil appears be qualitatively similar
to that of rivastigmine and galantamine in terms of the nature of
adverse events. However, in terms of relative frequency of adverse
events, there is level 1 evidence that fewer people had at least one
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table continued…
Level of
evidence
Design Treatment,
dose, duration
Disease progression measurement Time to
institutionalization
Reference
rCBF qEEG Other
3 MC, OL,
observational
follow-up of
patients
enrolled in
3 RCTs
DPZ 1, 3, 5, or
10 mg/day for
12 or 24 wk in
DB trial and
≥24 wk in OL
extension
(n=1115)
Median time to NHP
44.7 mo for minimal use
group, 66.1 mo for
maximal use group
(≥5 mg/day with ≥80%
compliance). Estimated
delay in NHP 17.5 mo
with DPZ ≥5 mg/day for
≥36–48 wk
Geldmacher
et al. 2003
aDose and duration not reported.
BL, baseline; CI, confidence interval; DB, double blind; DPZ, donepezil; HRR, hazard rate ratio; 123I QNB, 123I quinuclidinyl benzilate; MC, multicenter; mo, month; NHP, nursing home
placement; NR, not reported; NSD, no statistically significant difference; OL, open label; PL, placebo; pts, patients; qEEG, quantitative electroencephalogram; rCBF, regional cerebral blood
flow; RCT, randomized controlled trial; RIV, rivastigmine; SD, statistically significant difference; wk, week; y, year.211
adverse event with donepezil compared with rivastigmine, although
the difference was not significant (43 vs 58%, relative risk 0.74)
(Warner et al. 2004). The between-group difference in number of
patients discontinuing treatment, however, was significant in favor
of donepezil (11 vs 31%, relative risk 0.35). Similar rates of adverse
events, severe adverse events, and adverse events leading to
withdrawal were reported in galantamine- and donepezil-treated
patients (Warner et al. 2004). This is supported by level 3 evidence
from 6- and 9-month open-label trials (Aguglia et al. 2004; Mossello
et al. 2004). In one study, patients were administered donepezil
(n=256), rivastigmine (n=132), or galantamine (n=19) (Mossello et al.
2004). The percentage of patients that discontinued treatment was
significantly lower in the donepezil group (3%) than in the
rivastigmine (17%, P<0.01) or galantamine groups (21%, P<0.01),
although the number of patients in the galantamine group was low.
In another study of patients treated with donepezil (n=70),
rivastigmine (n=121), or galantamine (n=51), the most common
adverse events were gastrointestinal and the frequency of these
events were similar in all treatment groups (<6% for each event)
(Aguglia et al. 2004).
Thus, there is strong evidence that donepezil is well tolerated and
that the most common adverse events can be predicted from its
cholinergic mechanism of action. Also, the frequency of these
adverse events appears to be dose related. There is some
evidence that the incidence of adverse events is lower outside of
the clinical trial setting, although a wide variation in percentages
was observed in open-label studies.
Economic evidence
Alzheimer’s disease is a chronic and progressive condition with
no cure and presents a variety of challenges for patients and
their families, caregivers, and healthcare providers, as
discussed in the Disease overview section. Evaluation of the
economic impact of the disease requires consideration of three
broad categories of costs: direct, indirect, and intangible costs
(Leung et al. 2003; Table 13). However, inconsistent assessment
of these variables and geographic differences in care patterns
have produced highly variable cost-of-illness estimates. For
example, in an assessment of 23 economic studies, estimations
of annual costs per Alzheimer’s disease patient ranged from
$US5799 to $US75 490 (Leung et al. 2003). These estimates
were affected mainly by the inclusion or exclusion of costs
associated with long-term care, unpaid caregiving, and
institutionalization. 
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Level of
evidence
Design Treatment, dose,
duration
Outcome Reference
Quality of life Caregiver burden
1 Systematic review DPZa Improvements, no change, and
worsening reported (3 trials)
NICE 2005
1 Systematic review DPZ, NR, 12 or
24 wk
NSD in patient-rated quality of life Warner et al.
2004
1 Systematic review DPZ 5 or 10 mg/day,
12 or 24 wk
No evidence of benefit  Carer stress assessed in 1 study but results reported
without any measure of precision
Birks &
Harvey
2003b
DPZ 10 mg/day,
24 wk
SD vs PL in time spent/day by carer assisting with
IADL and PSMS: MD –81.9 min (P=0.02) (1 study)
1 Systematic review DPZ 5 or
10 mg/day, NR
Of 4 RCTs, 3 showed NSD and
1 significant worsening vs PL
Clegg et al.
2002
2 MC, DB, RCT DPZ 5–10 mg/day
(n=96) or PL (n=94),
12 mo
Increase in caring time from BL (assessed by RUD)
significantly lower in DPZ vs PL group (42.6 vs 106.8
min, P=0.03) at 12 mo
Wimo et al.
2004
2 MC, DB, RCT DPZ 5 or 10 mg/day
(n=283) or PL
(n=283), ≤3 y
After 2 y, NSD vs PL for carer psychologic morbidity,
active daily time input, passive care time, and unpaid
caregiver time 
Courtney
et al. 2004
3 OL DPZ 5 or 10 mg/day
(n=913), 3 mo
Improvement in 70% of patients Frölich et al.
2002
3 Survey of
Alzheimer patient
caregivers,
matched control
DPZ, NR (n=274) or
untreated control
(n=274), ≥9 mo
SD in favor of DPZ between 2 groups of caregivers
on total difficulty scale (P=0.004). NSD on demand
scale
Fillit et al.
2000
aDose and duration not reported.
bAssessment included patients with mild, moderate, or severe dementia due to Alzheimer’s disease.
BL, baseline; DB, double blind; DPZ, donepezil; IADL, Instrumental Activities of Daily Living; MC, multicenter; MD, mean difference; min, minute; mo, month; NR, not reported; NSD, no
statistically significant difference; OL, open label; PL, placebo; PSMS, Physical Self-Maintenance Scale; RCT, randomized controlled trial; RUD, Resource Utilization in Dementia questionnaire;
SD, statistically significant difference; wk, week; y, year.
Table 11 | Effects of donepezil on quality of life and caregiver burden
 Most of the economic analyses performed with donepezil have
been modeling studies (Jönsson et al. 1999; Neumann et al. 1999;
O’Brien et al. 1999; Ikeda et al. 2002; Fagnani et al. 2004).
However, a review of AChEI modeling studies concluded that,
because of methodologic considerations, their validity is difficult
to judge (Wimo 2004). There are few publications of empiric
economic data from RCTs of AChEIs (Wimo 2004) and only two
prospective studies were identified that examined the economic
impact of donepezil treatment in patients with mild to moderate
Alzheimer’s disease (Courtney et al. 2004; Wimo et al. 2003b).
One evaluation was performed as an adjunct to a 1-year, placebo-
controlled clinical trial of donepezil (Wimo et al. 2003b). This
economic “piggyback” evaluation was regarded as a reasonable
approach, although the authors acknowledge that dedicated
large-scale and long-term economic studies should be performed
with adequate powering for economic variables. The AD2000
study also incorporated an economic evaluation (Courtney et al.
2004). However, as mentioned previously, the design and
conclusions of this 3-year study have been criticized due to
recruitment of only one fifth of the intended number of patients
and high discontinuation rates at the end of the first and second
years (Akintade et al. 2004; Holmes et al. 2004a). 
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Number of patients,
duration of study
Incidence of AEs Most common AEs Discontinuation
due to AEs 
Other Reference
237, 24 wk 73%; most mild to
moderate and transient
Agitation (25%), fatigue
(15%), headache (14%),
insomnia (13%),
confusion (12%)
12%. Most frequently
cardiovascular events,
agitation, nausea or
vomiting, muscle
cramps, urinary
incontinence
Global tolerability rated as very
good/good in 81% of patients
Froelich et al.
2004
256, 9 mo NR No major drug-related
AEs observed. No detail
given
8 patients (3%):
behavioral (4 patients)
gastrointestinal (3),
pulmonary (1)
SD between DPZ and RIV (3 vs 17%,
P<0.01), DPZ and GAL (3 vs 21%,
P<0.01) in percentage discontinuation 
Mossello
et al. 2004
2094, 3 mo 12.2%  Nausea (2.2%), diarrhea
(1.4%), trembling inside
(1.4%), vomiting (1.1%)
6.1% (55.4% of
discontinuations)
Global tolerability judged by investigators
as “very good” or “good” in 91.3% of
patients assessed (n=1989). SAEs
reported in 46 patients (2.2%);
10 considered possibly/probably related
to DPZ treatment
Hager et al.
2003a
1035, 12 wk 70%; 64% mild Diarrhea (10%), nausea
(9%)
6.2%. Most common
causes: agitation,
confusion, dizziness,
headache, nausea (6
patients each; 0.6%
each)
SAEs reported for 94 patients (9%);
34 (3%) considered related to DPZ
Relkin et al.
2003
200, 24 wk 69% Nausea (8%),
depression (6%),
headache (6%),
abdominal pain (5%)
8.1% SAEs reported in 18 patients (9.1%);
none attributable to DPZ 
Santens &
Ventura 2003
913, 3 mo 9.3% Nausea (2.4%),
restlessness/agitation
(1.4%), sleep
disturbances (1.3%),
diarrhea (1.3%),
vomiting (1.1%)
3.5% SAEs reported in 14 patients (1.5%) Frölich et al.
2002
108, 12 mo 96%   Pain (27 patients),
diarrhea (24), nausea
(23), dizziness (20),
headache (19), dyspepsia
(15), influenza-like
symptoms (15)
10 patients: anxiety (2),
weight loss (2), diarrhea
(1), pacing (1), transient
ischemic attack (1),
confusion (1), agitated
depression (1), foot
pain (1)
22 SAEs in 16 patients; none had clear
relation to DPZ
Rockwood
et al. 2002
aIncluded patients with severe Alzheimer’s disease.
AE, adverse event; DPZ, donepezil; GAL, galantamine; mo, month; NR, not reported; RIV, rivastigmine; SAE, serious adverse event; SD statistically significant difference; wk, week.
Table 12 | Tolerability of donepezil reported in open–label trials that included more than 100 patients (level 3 evidence)
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Therefore, there are limited economic data with donepezil in mild
to moderate Alzheimer’s disease. Further limitations can be
identified when the available evidence is assessed in the context
of two common observations that underlie most Alzheimer’s
disease cost-of-illness estimates (Leung et al. 2003):
1. the costs of informal, unpaid caregiver time make up an
unusually large share of total costs (40–70%) compared with
other diseases
2. there is a strong correlation between disease severity or
functional impairment and the associated costs of care. 
Level 1 evidence suggests there have been few quantitative
assessments of the contribution of unpaid caregiver time to the
overall cost of donepezil treatment (Clegg et al. 2002; Wolfson et
al. 2002; Leung et al. 2003; Wimo 2004; NICE 2005). This is an
important observation as, following the introduction of drug
regimens, cost burdens may be shifted from institutional to home
care, resulting in savings to society as a whole (Leung et al. 2003).
There is level 2 evidence that donepezil is cost effective when
caregiver costs are considered (Wimo et al. 2003b). In a 1-year,
double-blind, randomized study, patients with mild to moderate
Alzheimer’s disease received either donepezil (n=142; 5 mg/day
for 28 days then 10 mg/day according to the clinician’s judgment)
or placebo (n=144). Mean annual patient-related healthcare costs
were $US16 438 per patient for the donepezil group and
$US16 147 in the placebo group. When caregiver costs (time- and
healthcare-related) were included, mean annual costs increased
to $US24 969 per patient in the donepezil group and $US26 066
in the placebo group. The total saving associated with donepezil
treatment was $US1097 per patient (95% confidence interval
–5246, 3053; P=0.6), leading the authors to conclude that
donepezil treatment was associated with no increase in cost to
society compared with placebo treatment over 1 year. It is also
noteworthy that caregiver time-related costs represented
approximately one third of the total cost in each treatment group,
emphasizing the importance of including costs of informal care in
economic evaluations of mild to moderate Alzheimer’s disease.
A modeling study of French patients with mild to moderate
Alzheimer’s disease provides further evidence (level 3) of the
importance of including unpaid caregiver time in cost-effectiveness
assessments (Fagnani et al. 2004). Costs considered in the
economic model were net societal costs associated with paid and
unpaid assistance, general medical consumption, and institutional
care. Over a 3-year period, total net costs of caring for untreated
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Direct costs Indirect costs Intangible costs
Direct medical costs
Preventive services (including screening of high-risk individuals)
Productivity losses (for both patients and
caregivers)
Monetarized value of the psychologic burden
and stress on patients and caregivers and of
the decrease in quality of life
Diagnostic services
Doctor consultations (generalist and specialist)
Laboratory and imaging tests (e.g. MRI, SPECT)
Opportunity costs of time spent by patients
and caregivers (travel, waiting for providers,
hospital stays)
Treatment and care services
Physician services
Pharmaceuticals/drugs
Medical and nursing procedures
Physiotherapy and other allied professional
(e.g. rehabilitation) services
Hospitalization and day hospitals
Nursing home care
Respite care
Caregiver support and training programs
Direct personal costs
Transportation
Homecare services (personal and nursing)
Equipment and aid supplies used in the home
Home modifications/alterations
Direct nonhealthcare costs
Social services and allowances
Meal delivery services
Group homes/special care units
MRI, magnetic resonance imaging; SPECT, single photon emission computed tomography.
Table 13 | Major direct, indirect, and intangible costs associated with Alzheimer’s disease (reproduced with permission from
Leung et al. Dement Geriatr Cogn Disord. 2003;15:34–43. S. Karger AG, Basel)
 patients were €53 206 compared with €42 720 for a patient treated
with donepezil, representing an annual cost saving of
approximately €3500 per patient (Fig. 2). The cost savings were
mainly due to savings in unpaid caregiver time, which, apart from
patient institutionalization, represented the most costly component
of total care in this study but had no direct budgetary impact.
Correlation between the progression of Alzheimer’s disease and
increased costs of care means it is important to assess the long-
term economic benefits of donepezil treatment. However, as
mentioned previously, most economic studies have been based
on projections and modeling rather than empiric observations
from RCTs with an adequate follow-up period (Leung et al. 2003;
Wimo 2004). Also, inconsistent methodologies make it difficult to
compare study results. This is likely to account for the
differences in study conclusions highlighted in level 1 evidence
(Clegg et al. 2002; Wolfson et al. 2002; Leung et al. 2003; NICE
2005). Leung et al. (2003) identified five cost-effectiveness
studies, of which three were cost saving, while two showed that
donepezil treatment carried a cost (Leung et al. 2003). Another
systematic review found seven studies, three of which
demonstrated cost saving, two indicated cost neutrality, and a
further two that showed an incremental cost with donepezil
(Wolfson et al. 2002). 
In an assessment of donepezil, rivastigmine, and galantamine,
Clegg et al. (2002) concluded that cost effectiveness was
uncertain and the impact on different care sectors had been
inadequately investigated. Five donepezil studies were identified,
which produced a very wide range of estimates. Two reported
cost savings of £2011 to £2415 per year in nonsevere states for
all cases. Another study estimated costs of £1210 and £7048 per
year in nonsevere states for mild and moderate cases,
respectively. A further study estimated costs of £6054 and
£49 476 per quality-adjusted life-year (QALY) for mild and
moderate cases, respectively, and the fifth did not report a base
case, so was not considered by the authors. Overall, the cost
estimates for donepezil in Alzheimer’s disease were not
considered to be robust or generalizable. 
The NICE Assessment Group identified 11 studies, five of which
indicated cost saving for donepezil treatment (NICE 2005). One
study, based on drug costs alone, estimated a cost per QALY
gained (CQG) for the 5 mg/day dose of £21 000 (2-year model) to
£86 000 (10-year model) for a gain of 0.08 QALYs per person. The
NICE Assessment Group also used their own model to estimate
cost effectiveness of AChEIs plus usual care versus usual care
alone in a UK context from the perspective of a third-party payer.
Cohorts of 1000 patients with mild to moderate Alzheimer’s
disease were modeled in a Markov disease progression model.
The difference between the AChEI plus usual care and usual care
groups in time spent in full-time care over 5 years ranged from
1.43 to 1.6 years, and QALYs gained ranged from 0.042 to 0.048.
The resulting base case CQG was £94 000 for donepezil
10 mg/day.
The NICE Assessment Group concluded that the AChEIs are
outside the range of cost effectiveness that might be considered
appropriate for the UK NHS (NICE 2005). However, when the data
were reevaluated, the cost effectiveness of donepezil was
considered sufficiently acceptable to allow its prescription for
Alzheimer’s disease of moderate severity (NICE 2006). Concerns
with the original NICE analysis had been raised, particularly in the
use of CQG (Alzheimer’s Society 2005; DoH 2005; RCP 2005).
Weaknesses have been identified with this methodology in
modeling disease progression, obtaining good quality information
on costs for patients treated in the community, and sensitivity to
small changes in estimated incremental costs. Also, the UK
government’s Department of Health (DoH) highlighted the need to
compare the CQG of AChEIs with that of nondrug interventions
for cognition, behavior, ADLs, and caregiver burden. The DoH
also notes that withdrawal of AChEIs may lead to an increase in
the prescribing of more harmful medications, such as
antipsychotics, which should be considered in an assessment of
costs (DoH 2005). Criticism has also been made of the exclusion
of benefits to caregivers, in terms of quality of life, cost, time
spent caring or impact on their health, and the restricted focus on
utility for the individual recipient of the intervention (Alzheimer’s
Society 2005; DoH 2005; RCP 2005).
There have also been concerns regarding the methodology of the
AD2000 study, as outlined previously (Akintade et al. 2004;
Holmes et al. 2004a). This should be considered when assessing
level 2 evidence from this trial, which indicated that donepezil was
not cost effective, mainly because of no apparent benefits in
delaying disease progression or time to institutionalization
(Courtney et al. 2004). There was also no significant difference
between the donepezil and placebo groups in mean annual cost
per patient resident in the community for 11 formal health and
social services (£2842 vs £2344, P=0.16). Informal care was not
costed because there were no significant differences in active and
passive caregiver daily time input.
In contrast, there is level 3 evidence from a matched case–control
study, which also did not include informal care costs, supporting
the cost effectiveness of donepezil (Hill et al. 2002). Costs for
204 donepezil-treated patients were compared with a group of
204 untreated patients, controlling for age, gender, pharmacy
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benefits, comorbid conditions, and complications of dementia.
Annual costs for medical services and prescription drugs were
significantly lower for the treatment group (difference $US3891,
P=0.016). This difference was largely attributable to significantly
lower costs for inpatient hospital (P=0.025) and skilled nursing
facility services (P=0.0001). Similarly, a retrospective analysis of
patients with early-stage Alzheimer’s disease found that annual
healthcare costs were $US2408 lower for 428 patients treated
with an AChEI (one patient received tacrine, remainder donepezil)
than for patients not receiving therapy (Fillit et al. 2002). Another
case–control study conducted by the same research group
included data from 229 patients treated with donepezil and
458 untreated patients (control group) (Lu et al. 2005). The mean
cost of medical services per year in the donepezil group was
$US2500 less than in the control group (P=0.024). Lower medical
costs in the donepezil group were largely attributable to the lower
costs of services performed in the hospital (P<0.004) and
postacute skilled nursing facility (P<0.001). Patients receiving
donepezil also had shorter mean lengths of stay in the hospital
(3 vs 5.4 days, P<0.008) but a higher mean number of physician’s
office visits (10.9 vs 7.9, P<0.001). 
Thus, there are clearly many factors to be taken into account
when assessing the cost effectiveness of any intervention in
Alzheimer’s disease. There is some evidence that treatment with
donepezil is cost effective when unpaid caregiver time is
considered, which is representative of the real-life situation for
most patients. However, the existing evidence for donepezil is
conflicting and, because of methodologic considerations, the
validity of much of the available data is difficult to judge. RCTs
with long-term follow-up are required to confirm the cost
effectiveness of donepezil, taking into account multiple factors to
calculate utility for both patients and caregivers. 
Resource utilization
Alzheimer’s disease is associated with significant resource
utilization resulting from the direct and indirect costs of caring by
family and friends as well as the costs of medical and institutional
care (see The burden of illness section). In terms of drug
treatment, expenditure on AChEIs is expected to increase. For
example, in the UK, the NICE Assessment Group reported that
NHS expenditure on AChEIs in the financial year 2003–2004 was
approximately £48 million (NICE 2005). Based on 2001–2004
trends, this expenditure was expected to increase to at least
£70 million in 2005–2006. 
However, as discussed in the Economic evidence section, cost of
drug treatment is one of many different elements that must be
considered to gain an accurate picture of resource utilization in
Alzheimer’s disease. Table 13 lists the major direct, indirect, and
intangible costs associated with Alzheimer’s disease (Leung et al.
2003). Direct medical costs include costs or savings directly
related to the interventions for Alzheimer’s disease, costs induced
or averted as a result of the intervention or information provided by
it, costs required to manage adverse events or complications
caused by the intervention, and all additional healthcare resources
needed to treat conditions that occur during added years of life
expectancy. Direct personal costs include transportation expenses
to and from care facilities, costs of providing services in the home
and community, and of support services for recuperation,
rehabilitation, and coping with Alzheimer’s disease. Direct
nonhealthcare costs or savings are met by facilities such as
welfare, housing, and education. Indirect costs and savings
include changes in the productive use of time by patients and
others. Intangible costs of illness provide a measure of the
psychologic burden and stress on patients, families, and
caregivers, and of any improvements in quality of life. 
Any cost savings associated with AChEI treatment are likely to
result mainly from delayed disease progression and delayed
institutionalization, reduced hospital, emergency, and home care
costs, reduced burden on unpaid caregivers, and improved
quality of life. Estimates of resource utilization are included in
many studies of donepezil, but are usually not readily identifiable
when not included as primary outcomes. In general, however,
there is some evidence, mainly from open-label trials, to suggest
that donepezil treatment delays disease progression and time to
institutionalization. There is also some evidence to suggest
donepezil may lessen caregiver burden, particularly in terms of
caring time. However, there is no strong evidence to suggest that
donepezil improves patients’ quality of life, with mixed results
reported. Although there is therefore some evidence of benefit
from donepezil on the major determinants of resource utilization,
assessment of all areas points to the need for more robust data to
confirm its impact.
Patient group/population
There is evidence to support the indication of donepezil for the
symptomatic treatment of mild to moderate Alzheimer’s disease,
especially in terms of global outcomes, cognition, and function.
There is no strong evidence of efficacy in particular subpopulations
of patients with mild to moderate symptoms. There is evidence of
efficacy in the treatment of mild cognitive impairment (Salloway et
al. 2004; Petersen et al. 2005) and severe Alzheimer’s disease
(Gauthier et al. 2002; Birks & Harvey 2003; Hager et al. 2003;
Feldman et al. 2004). Although some of the patient entry criteria
scores in these studies overlap with those of patients with mild to
moderate Alzheimer’s disease, donepezil is not indicated in these
patient populations at this time. The manufacturer has filed with
the Food and Drug Administration for approval in the severe
Alzheimer’s disease indication (Anon. 2005b).
Dosage, administration, and formulations
Donepezil (Aricept) is indicated for the symptomatic treatment of
mild to moderate Alzheimer’s disease. It is available as round, film-
coated tablets each containing donepezil hydrochloride 5 or 10 mg.
It is also available as an orally disintegrating tablet formulation.
The recommended dose of donepezil is 5 or 10 mg once daily.
Although not unequivocally proven in clinical trials, there is some
evidence to suggest that a daily donepezil dose of 10 mg may
provide additional benefit in some patients compared with a daily
dose of 5 mg (Birks & Harvey 2003; Whitehead et al. 2004).
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prescriber and patient preference and should not be made until
the patient has been on a daily dose of 5 mg for 4–6 weeks. In
comparison with titration over 1 week, titration over 4–6 weeks
appears to reduce the frequency of adverse events (Anon. 2005a).
Donepezil should be taken in the evening, just before retiring, and
may be taken with or without food (Anon. 2005a).
Clinical value
The evidence summary table at the beginning of this article
summarizes the clinical evidence for the impact of donepezil on
clinical and economic outcome measures. There is evidence that
donepezil has efficacy against the three major domains of
Alzheimer’s disease symptoms, namely functional ability,
behavior, and cognition. The strongest evidence is for
improvement or less deterioration in global outcomes and
cognition in the short to medium term. There is some evidence
that improved global outcomes are maintained in the long term
and clear evidence to support the long-term maintenance of
cognitive benefits. Also, there is strong evidence of maintained
function in the long term. Therefore, there is substantial evidence
to suggest that donepezil treatment stabilizes cognitive and
functional symptoms in the long term. Although some level 1 and
2 evidence supports improved or limited deterioration in behavior
or mood in the short to medium term, no evidence exists for a
long-term effect against this particular symptom.
Despite evidence that donepezil has an effect on a patient’s overall
or global health state and major symptoms of Alzheimer’s disease,
studies to date have provided inconsistent results concerning
effect on patients’ quality of life. This may reflect the difficulty of
assessing quality of life in individuals with cognitive disabilities
(Andersen et al. 2004) and points to the need for more studies on
this aspect of Alzheimer’s disease (Alzheimer’s Society 2005). 
There are few long-term data on disease progression, with most
of the evidence coming from studies of disease-oriented rather
than patient-oriented outcomes. Donepezil has some effect on
markers of brain function and volume, and further evaluation of a
neuroprotective effect is required. One trial (level 2 evidence)
provides some evidence of an effect on progression from mild
cognitive impairment to Alzheimer’s disease, with reduced
likelihood of such progression at 12 months but not at 3 years.
There is limited and conflicting evidence to suggest that long-
term donepezil treatment delays time to institutionalization.
There is strong evidence that donepezil is well tolerated and the
most common adverse events are predictable. There is evidence
from observational studies that this good tolerability profile is
maintained or may even be improved in community-based clinical
practice.
Evidence that donepezil may lessen caregiver burden has some
relevance to economic assessments of donepezil, which require
many factors to be taken into account including costs met by
unpaid caregivers. Consideration of the acquisition and
administration costs of donepezil in isolation reveals no cost-
saving benefit. However, some evidence supports the cost
effectiveness of donepezil when unpaid caregiver costs are
included to reflect community-based clinical practice.
Furthermore, preliminary guidance from NICE states that the cost
effectiveness of donepezil is sufficiently acceptable to allow its
prescription in England and Wales for Alzheimer’s disease of
moderate severity (NICE 2006).
In summary, AChEIs are the only agents recommended for the
treatment of cognitive decline in patients with mild to moderate
Alzheimer’s disease. There is strong evidence that donepezil is
more effective than placebo and is well tolerated in improving the
major symptoms of this disease. Improvements are usually
modest, although stabilization of cognitive and functional
symptoms with donepezil can also be considered an important
clinical outcome. There is some evidence that donepezil lessens
caregiver burden, a significant outcome given the long-term and
progressive nature of the disease. This suggests that alleviation of
symptoms with donepezil may reduce the burden for patients and
their caregivers, especially when compared with no treatment.
Also, there is some evidence that donepezil may be cost saving,
especially when unpaid caregiver costs are included. More data
are required from RCTs with long-term follow-up to confirm its
cost effectiveness and the impact of donepezil treatment on
quality of life, disease progression, and time to institutionalization.
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